MILATAXEL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C44H55NO16
Molecular Weight	853.9046
Optical Activity	( - )
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CO6)C(C)=C([C@@H](O)C(=O)[C@]13C)C5(C)C

InChI

InChIKey=XIVMHSNIQAICTR-UQYHODNASA-N

InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C44H55NO16
Molecular Weight	853.9046
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	11 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17516069 | https://clinicaltrials.gov/ct2/show/NCT00685204 | https://clinicaltrials.gov/ct2/show/NCT00063219

Milataxel, a taxane that binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization. Milataxel has completed phase II clinical trials for non-small cell lung cancer patients, and for colorectal cancer patients. Besides, it was studied for malignant mesothelioma. However, the drug has been discontinued due to toxicity issues at the dose level of 35 mg/m 2.

Originator

Approval Year

PubMed

Title	Date	PubMed
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.	2008-03	17516069
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.	2003-09	14555706

Sample Use Guides

In Vivo Use Guide

patients with advanced colorectal cancer: milataxel was administered intravenously every 3 weeks at the dose of 35 mg/m(2). Malignant Mesotheliom: milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:43:19 GMT 2025` Edited by `admin` on `Mon Mar 31 22:43:19 GMT 2025`
Record UNII	J41Q4S20GS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MILATAXEL

Official Name

English

MAC-321

Preferred Name

English

milataxel [INN]

Common Name

English

MILATAXEL [USAN]

Common Name

English

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(1-oxopropoxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (?R,?R)-?-[[(1,1-dimethyleth

Systematic Name

English

2-Furanpropanoic acid, ?-[[(1,1-dimethylethoxy)carbonyl]amino]-?-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-6,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(1-oxopropoxy)-7,11

Systematic Name

English

Code System Code Type Description

PUBCHEM

6918589